SynthesisPloS one2016
Meta-Analysis and Advancement of Brucellosis Vaccinology.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- What risk do Brucella vaccines pose to humans? A systematic review of the scientific literature on occupational exposure.PLoS neglected tropical diseases · 2024Pooled it
- Efficacy ofTransboundary and emerging diseases · 2024Pooled it
- Quantitative proteomics identifies GntR as a novel potential DIVA antigen for bovine brucellosis.Applied microbiology and biotechnology · 2026Article
- Innate Immunity Trained in the Protective Response of Vaccine Candidates Against Intracellular Pathogens.Vaccines · 2026Article
- A novel IgG-Fc-Fused multiepitope vaccine against Brucella: robust immunogenicity.Microbial cell factories · 2025Article
- In Silico Design and Characterization of a Multiepitope Vaccine Candidate AgainstJournal of immunology research · 2025Article
- Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives.Frontiers in medicine · 2025Review
- Hypertonic Saline Induces Host Protective Immune Responses againstJournal of microbiology and biotechnology · 2024Article
- Comparative study on alginate/chitosan microcapsules and Montanide ISA 61 as vaccine adjuvants in mice.PloS one · 2024Article
- Development of a candidate multi-epitope vaccine againstSaudi medical journal · 2023Article
- Cell and Tissue Tropism of Brucella spp.Infection and immunity · 2023Review
- Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design.Pathogens and global health · 2023Review
- Article
- Intratracheal inoculation results in Brucella-associated reproductive disease in male mouse and guinea pig models of infection.Frontiers in microbiology · 2022Article
- Proteome Based Approach Defines Candidates for Designing a Multitope Vaccine against the Nipah Virus.International journal of molecular sciences · 2021Article
- In Silico Prediction of a Multitope Vaccine againstVaccines · 2021Article
- Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.Veterinary research · 2021Article
- Epitope-Based Vaccine of aFrontiers in immunology · 2021Article
- Canine Brucellosis: An Update.Frontiers in veterinary science · 2021Review
- Intratracheal Inoculation with Brucella melitensis in the Pregnant Guinea Pig Is an Improved Model for Reproductive Pathogenesis and Vaccine Studies.Infection and immunity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesIn spite of all the research effort for developing new vaccines against brucellosis, it remains unclear whether these new vaccine technologies will in fact become widely used. The goal of this study was to perform a meta-analysis to identify parameters that influence vaccine efficacy as well as a descriptive analysis on how the field of Brucella vaccinology is advancing concerning type of vaccine, improvement of protection on animal models over time, and factors that may affect protection in the mouse model.
methodsA total of 117 publications that met the criteria were selected for inclusion in this study, with a total of 782 individual experiments analyzed.
resultsAttenuated (n = 221), inactivated (n = 66) and mutant (n = 102) vaccines provided median protection index above 2, whereas subunit (n = 287), DNA (n = 68), and vectored (n = 38) vaccines provided protection indexes lower than 2. When all categories of experimental vaccines are analyzed together, the trend line clearly demonstrates that there was no improvement of the protection indexes over the past 30 years, with a low negative and non significant linear coefficient. A meta-regression model was developed including all vaccine categories (attenuated, DNA, inactivated, mutant, subunit, and vectored) considering the protection index as a dependent variable and the other parameters (mouse strain, route of vaccination, number of vaccinations, use of adjuvant, challenge Brucella species) as independent variables. Some of these variables influenced the expected protection index of experimental vaccines against Brucella spp. in the mouse model.
conclusionIn spite of the large number of publication over the past 30 years, our results indicate that there is not clear trend to improve the protective potential of these experimental vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.